Abstract 456P
Background
As mentioned by ESMO guidelines on the management of constipation in advanced cancer, combined opiate/naloxone medications have been shown to reduce the risk of OIC through a range of studies. Oxycodone/naloxone prolonged-release tablets (OXN PR) provide similar efficacy, but an improved bowel function compared with oxycodone prolonged-release tablets (OXY PR). This is the first Chinese study about OXN PR in cancer pain population.
Methods
This multi-center, randomized, double-blind controlled trial compared OXN PR to OXY PR for 4 weeks in adult cancer patients with moderate-to-severe pain and OIC. Primary efficacy endpoints: Bowel Function Index (BFI) and Brief Pain Inventory-Short Form (BPI-SF). Key secondary endpoints: use of laxative (bisacodyl tablets) and rescue analgesia (morphine sulfate), quality of life (EQ-5D) and safety.
Results
232 patients were randomized (117 in the OXN PR group; 115 in the OXY PR group). BPI-SF average pain was comparable after 4 weeks between OXN PR and OXY PR groups. The difference of average BFI at 4 weeks was not statistically significant between the 2 treatment groups (FAP, p=0.482). Compared to baseline, a BFI reduction was seen after 1 week in OXN PR group (13.5 points vs. 8.8 points in OXY PR group; p=0.039). Results of an exploratory post-hoc analysis confirmed these findings, with the BFI difference favoring OXN PR. Laxative use was similar between the 2 groups, but a higher percentage of patients required laxatives in OXY PR group compared to OXN PR group at all visits. Average daily dose and percentage of patients taking rescue analgesia were similar at 4 weeks. EQ-5D assessment showed a minor improvement in the OXN PR group and a decline in OXY PR group (non-significant). Fewer adverse events were reported in the OXN PR group (17.5% vs. 27.0% in the OXY PR group); No treatment-related SAEs were reported with OXN PR group.
Conclusions
In managing moderate-to-severe cancer pain among Chinese patients, OXN PR has demonstrated comparable efficacy to OXY PR. Improvements of bowel function were numerically observed and statistically confirmed by a post-hoc analysis (p=0.039). This study adds to the wealth of evidence around the positive benefit/risk profile of OXN PR in an Asian population.
Clinical trial identification
NCT00513656.
Editorial acknowledgement
Editorial assistance was provided by MedAcc Technology Co., Ltd.
Legal entity responsible for the study
Mundipharma (China) Pharmaceutical Co.LTD.
Funding
Mundipharma (China) Pharmaceutical Co.LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract